Contrasting Theratechnologies (NASDAQ:THTX) & NexImmune (NASDAQ:NEXI)

Theratechnologies (NASDAQ:THTX) and NexImmune (NASDAQ:NEXI) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, valuation, dividends and risk.

Risk and Volatility

Theratechnologies has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500. Comparatively, NexImmune has a beta of 1.98, suggesting that its share price is 98% more volatile than the S&P 500.

Institutional and Insider Ownership

9.9% of NexImmune shares are owned by institutional investors. 14.9% of NexImmune shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Theratechnologies and NexImmune’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Theratechnologies	-3.75%	N/A	-4.31%
NexImmune	N/A	-534.32%	-213.72%

Analyst Ratings

This is a summary of current ratings and target prices for Theratechnologies and NexImmune, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Theratechnologies	0	0	0	2	4.00
NexImmune	0	0	0	0	0.00

Valuation & Earnings

This table compares Theratechnologies and NexImmune”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Theratechnologies	$88.67 million	1.43	-$23.96 million	($0.08)	-34.44
NexImmune	N/A	N/A	-$32.34 million	($18.54)	0.00

Theratechnologies has higher revenue and earnings than NexImmune. Theratechnologies is trading at a lower price-to-earnings ratio than NexImmune, indicating that it is currently the more affordable of the two stocks.

Summary

Theratechnologies beats NexImmune on 7 of the 12 factors compared between the two stocks.

About Theratechnologies

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

About NexImmune

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company’s product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It provides NEXI-004 which is in preclinical stage for EBV related diseases; and NEXI005 designs for patient with specific targets for solid tumors. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.